Communication: order No. 0632 of 2021

IDENTIFIER
62021TB0632
LANGUAGE
English
COURT
General Court
AG OPINION
NO
REFERENCES MADE
2
REFERENCED
1
DOCUMENT TYPE
Communication: order

Judgment



16.5.2022   

EN

Official Journal of the European Union

C 198/50


Order of the General Court of 1 March 2022 — Agreiter and Others v Commission

(Case T-632/21) (1)

(Action for annulment - Medicinal products for human use - Amendment of the conditional marketing authorisation for Spikevax, a medicinal product for human use - COVID-19 mRNA Vaccine (nucleoside modified) - No interest in bringing proceedings - Lack of direct concern - Lack of individual concern - Inadmissibility)

(2022/C 198/74)

Language of the case: German

Parties

Applicants: Karin Agreiter (Merano, Italy) and the 33 other applicants whose names are listed in the Annex to the order (represented by: R. Holzeisen, lawyer)

Defendant: European Commission (represented by: L. Haasbeek and B.-R. Killmann, acting as Agents)

Re:

By their action under Article 263 of the TFEU, the applicants seek annulment of Commission Implementing Decision C(2021) 5686 final of 23 July 2021 amending the conditional marketing authorisation for ‘Spikevax’ — COVID-19 mRNA Vaccine (nucleoside modified), a medicinal product for human use granted by Implementing Decision C(2021) 94 final of 6 January 2021.

Operative part of the order

1.

The action is dismissed as inadmissible.

2.

There is no longer any need to adjudicate on the application for leave to intervene submitted by Moderna Biotech Spain SL.

3.

Ms Karin Agreiter and the other applicants whose names are listed in the Annex shall pay the costs.

4.

Moderna Biotech Spain shall bear its own costs related to the application for leave to intervene.


(1)  OJ C 471, 22.11.2021.



Citations

Sign up for a free moonlit.ai™ account to access all citing documents.